Current status and development of clinical drug research for prostate cancer
10.3969/j.issn.1005-6483.20241929
- VernacularTitle:前列腺癌临床药物研究现状与发展
- Author:
LI Xian MIAO
1
;
YIRIXIATIJIANG·AMIER
;
WU Huan LEI
;
Jia HU
Author Information
1. 430030 武汉,华中科技大学同济医学院附属同济医院泌尿外科
- Publication Type:Journal Article
- Keywords:
castration resistant prostate cancer;
drug therapy;
research progress
- From:
Journal of Clinical Surgery
2025;33(2):204-207
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is the most prevalent tumor of the urinary system globally and represents the highest incidence of malignant tumors among males in Europe and the United States.For recurrent or metastatic disease,androgen deprivation therapy is currently recognized as the cornerstone of treatment.However,nearly all patients inevitably progress to an incurable castration-resistant prostate cancer stage.Although the approval of several new drugs over the past two decades has enhanced both survival time and quality of life for patients with advanced prostate cancer,there remains an urgent challenge to develop new strategies that can overcome drug resistance and further extend survival duration.Therefore,based on published or ongoing clinical studies,this review will focus on an overview of the significant advancements made in the field of prostate cancer drug therapy,as well as new drugs that are actively undergoing clinical trials to provide a reference for the clinical treatment of advanced prostate cancer.
